Skip NavigationSkip to Content
Return Return to Search Results

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency

  1. Author:
    Halvas, E. K.
    Aldrovandi, G. M.
    Balfe, P.
    Beck, I. A.
    Boltz, V. F.
    Coffin, J. M.
    Frenkel, L. M.
    Hazelwood, J. D.
    Johnson, V. A.
    Kearney, M.
    Kovacs, A.
    Kuritzkes, D. R.
    Metzner, K. J.
    Nissley, D. V.
    Nowicki, M.
    Palmer, S.
    Ziermann, R.
    Zhao, R. Y.
    Jennings, C. L.
    Bremer, J.
    Brambilla, D.
    Mellors, J

  2. Author Address

    Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA. Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA. Columbia Univ, New York, NY USA. Univ Washington, Seattle, WA 98195 USA. NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. Univ So Calif, Los Angeles, CA USA. Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA. Harvard Univ, Sch Med, Div AIDS, Boston, MA USA. Univ Erlangen Nurnberg, Erlangen, Germany. NCI, Basic Res Program, SAIC Frederick, Frederick, MD 21701 USA. Bayer Healthcare Diagnost, Berkeley, CA USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Rush Med Coll, Chicago, IL 60612 USA. New England Res Inst, Watertown, MA 02172 USA.;Mellors, JW, Univ Pittsburgh, Dept Med, Div Infect Dis, S818 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.;Mellors@msx.dept-med.pitt.edu
    1. Year: 2006
    2. Date: Jul
  2. Journal: Journal of Clinical Microbiology
    1. 44
    2. 7
    3. Pages: 2612-2614
  4. Type of Article: Article
  5. ISSN: 0095-1137
  1. Abstract:

    We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1128/jcm.00449-06
  3. View record in Web of Science®
  4. WOS: 000239157400053

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel